Sun Pharma gets FDA approval for new device to treat skin disease

Sun Pharma and Moebius Medical announce dual publications on MM-II’s phase 2b clinical trial results in Osteoarthritis and Cartilage

Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles

Shaik Barak Tulla joins Sun Pharma as Sr. VP

Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla

US court lifts launch restrictions on Sun Pharma's autoimmune drug

Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI

Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis

Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers

Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise

Sun Pharma amongst top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025

This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability

Philogen completes patient enrollment of Phase III FIBROSARC trial in Soft Tissue Sarcoma

These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential

Sun Pharma to acquire 100% stake in Antibe Therapeutics

Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation

Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun

Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun